ClinicalTrials.Veeva

Menu

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Rigshospitalet logo

Rigshospitalet

Status

Unknown

Conditions

Urinary Bladder Neoplasm

Treatments

Other: Evaluation of muscle mass and muscle function

Study type

Observational

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Informed consent
  • Age ≥ 18 år
  • Histologically verified cancer of the renal pelvis, ureter, bladder or urethra regardless of type of histology
  • ECOG performance status 0 - 3
  • Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy for localized disease, chemotherapy or immunotherapy for disseminated disease).

Exclusion criteria

  • Age < 18

Trial design

30 participants in 1 patient group

Included patients
Description:
One-arm study. All included patients will have muscle mass and muscle function evaluated
Treatment:
Other: Evaluation of muscle mass and muscle function

Trial contacts and locations

1

Loading...

Central trial contact

Lise Hoej Omland, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems